Literature DB >> 14504850

Allele and genotype frequency of CYP2C9 in Tamilnadu population.

C Adithan1, N Gerard, S Vasu, R Balakrishnan, C H Shashindran, R Krishnamoorthy.   

Abstract

OBJECTIVES: To identify the frequency of CYP2C9*1, *2 and *3 alleles and the genotype of CYP2C9 gene in the Tamilian population.
METHODS: The study was conducted on 135 unrelated healthy human volunteers. DNA was extracted from the peripheral leukocytes samples and was analyzed using the polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) protocol. The PCR products were digested with AvaII, KpnI or NsiI restriction enzymes. The digested products were separated using 8% polyacrylamide gel and stained by ethidium bromide. Genotyping of the subjects was done based on DNA fragment size.
RESULTS: The frequencies of CYP2C9*1, *2 and *3 alleles in the Tamilian population were 0.907, 0.026 and 0.067, respectively. The distribution of CYP2C9*1/*1, *1/*2, *1/*3 and *2/*3 genotypes were 0.823, 0.044, 0.126 and 0.007, respectively.
CONCLUSION: CYP2C9*3 is the most frequent mutant allele found in the Tamilian population. The distribution of this mutant allele in the Tamilian population was found to be lesser than in Caucasians but higher than in Chinese.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14504850     DOI: 10.1007/s00228-003-0666-3

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  21 in total

Review 1.  Recent advances in P450 research.

Authors:  J L Raucy; S W Allen
Journal:  Pharmacogenomics J       Date:  2001       Impact factor: 3.550

2.  The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.

Authors:  T H Sullivan-Klose; B I Ghanayem; D A Bell; Z Y Zhang; L S Kaminsky; G M Shenfield; J O Miners; D J Birkett; J A Goldstein
Journal:  Pharmacogenetics       Date:  1996-08

3.  Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele.

Authors:  R S Kidd; A B Straughn; M C Meyer; J Blaisdell; J A Goldstein; J T Dalton
Journal:  Pharmacogenetics       Date:  1999-02

4.  Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.

Authors:  A E Rettie; L C Wienkers; F J Gonzalez; W F Trager; K R Korzekwa
Journal:  Pharmacogenetics       Date:  1994-02

5.  Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers.

Authors:  C Verstuyft; S Morin; A Robert; M A Loriot; P Beaune; P Jaillon; L Becquemont
Journal:  Pharmacogenetics       Date:  2001-11

6.  Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis.

Authors:  G P Aithal; C P Day; J B Leathart; A K Daly
Journal:  Pharmacogenetics       Date:  2000-08

Review 7.  Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs.

Authors:  Janyce F Rogers; Anne N Nafziger; Joseph S Bertino
Journal:  Am J Med       Date:  2002-12-15       Impact factor: 4.965

8.  Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.

Authors:  Julia Kirchheiner; Ingolf Meineke; Gunnar Müller; Ivar Roots; Jürgen Brockmöller
Journal:  Pharmacogenetics       Date:  2002-10

9.  Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese.

Authors:  S L Wang; J Huang; M D Lai; J J Tsai
Journal:  Pharmacogenetics       Date:  1995-02

10.  Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2.

Authors:  Julia Kirchheiner; Ingolf Meineke; Georg Freytag; Christian Meisel; Ivar Roots; Jürgen Brockmöller
Journal:  Clin Pharmacol Ther       Date:  2002-07       Impact factor: 6.875

View more
  12 in total

1.  Analysis of CYP2C9 polymorphisms (*2 and *3) in warfarin therapy patients in Pakistan. Association of CYP2C9 polymorphisms (*2 and*3) with warfarin dose, age, PT and INR.

Authors:  Faiza Yasmeen; Muhammad Bilal Ghafoor; Abdul Wadood Khalid; Waqas Latif; Shahida Mohsin; Shagufta Khaliq
Journal:  J Thromb Thrombolysis       Date:  2015-08       Impact factor: 2.300

2.  Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients.

Authors:  Ramasamy Kesavan; Sunil K Narayan; Chandrasekaran Adithan
Journal:  Eur J Clin Pharmacol       Date:  2010-07       Impact factor: 2.953

3.  Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients.

Authors:  A Surendiran; S C Pradhan; Aparna Agrawal; D K S Subrahmanyam; S Rajan; D Anichavezhi; C Adithan
Journal:  Eur J Clin Pharmacol       Date:  2011-02-20       Impact factor: 2.953

4.  Glutathione S-transferase M1 and T1 null genotype distribution in South Indians.

Authors:  A T Naveen; C Adithan; N Padmaja; C H Shashindran; B K Abraham; K Satyanarayanamoorthy; P Anitha; N Gerard; R Krishnamoorthy
Journal:  Eur J Clin Pharmacol       Date:  2004-06-10       Impact factor: 2.953

5.  Cytochrome P450 2C9 (CYP2C9) polymorphisms in Chinese Li population.

Authors:  Yipeng Ding; Danlei Yang; Long Zhou; Ping He; Jinjian Yao; Pingdong Xie; Daobo Lin; Dingwei Sun; Pei Sun; Quanni Li; Tingting Geng; Tianbo Jin
Journal:  Int J Clin Exp Med       Date:  2015-11-15

6.  Genetic Polymorphism of Cytochrome p450 (2C9) Enzyme in Iranian Baluch Ethnic Group.

Authors:  Mojdeh Ghiyas Tabari; Fatemeh Naseri; Maryam Agh Ataby; Abdoljalal Marjani
Journal:  Open Biochem J       Date:  2015-07-31

7.  Association of cytochrome P450 2C9 polymorphism with locally advanced head and neck squamous cell carcinoma and response to concurrent cisplatin-based radical chemoradiation.

Authors:  Sayan Paul; Tamojit Chaudhuri; M C Pant; D Parmar; Kirti Srivastava
Journal:  South Asian J Cancer       Date:  2014-07

8.  Association of polymorphism in cytochrome P450 2C9 with susceptibility to head and neck cancer and treatment outcome.

Authors:  Sunishtha S Yadav; Shilpi Seth; Anwar J Khan; Shailendra S Maurya; Ankur Dhawan; Sidharth Pant; Mohan C Pant; Devendra Parmar
Journal:  Appl Transl Genom       Date:  2013-08-27

9.  Effect of anti-tuberculosis therapy on polymorphic drug metabolizing enzyme CYP2C9 using phenytoin as a probe drug.

Authors:  Melvin George; Deepak Gopal Shewade; Saka Vinod Kumar; Chandrasekaran Adithan
Journal:  Indian J Pharmacol       Date:  2012 Jul-Aug       Impact factor: 1.200

10.  Cytochrome P450 2C9 gene polymorphism in phenytoin induced gingival enlargement: A case report.

Authors:  S P K Kennedy Babu; V Ramesh; Agila Samidorai; N S C Charles
Journal:  J Pharm Bioallied Sci       Date:  2013-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.